Bone marrow mononuclear cells for ischemic cardiac failure - a prospective, controlled, randomized, double-blinded study of cell transplantation combined with coronary bypass surgery

      Worldwide, millions of people are killed every year by ischemic heart failure. Bone marrow mononuclear cell (BMMC) transplantation is a promising new method to treat heart failure but results from clinical trials have been mixed. Here, we present results from our study combining BMMC therapy with coronary bypass surgery (CABG).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect